Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.


Pancreatic Cancer Clinical Trials

Newly diagnosed, previously untreated patients with metastatic pancreatic cancer

A Phase 1a/b Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy (NCI# NCT04068896)

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (NCI# NCT03611556)

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT) (NCI# NCT04233866)

Newly diagnosed, previously untreated patients with localized pancreatic cancer who are candidates for surgical resection

Initial Feasibility Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer (NCI# NCT02843945)

RT-155: Utilizing Pulsed Low-dose-rate (PLDR) Radiation to Prevent de Novo Stromal Activation; a Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial (NCI# NCT04452357)

Non-interventional studies, correlative and biomarker studies

A Pilot Study of Caregiver Adjustment and Quality of Life among Pancreatic Cancer Patients

Patients with previously treated metastatic pancreatic cancer

Fox Chase has a robust phase I clinical trials program with a number of trials open for those who have been previously treated for metastatic pancreatic cancer. You can search for open phase I clinical trials for pancreatic cancer here.

Connect with Fox Chase